Alnylam’s HELIOS-B Review: Conflicting Insights Analyzed by Lilu Anderson 25.06.2024 Explore conflicting analyst opinions on Alnylam's HELIOS-B data, contrasting efficacy views for vutrisiran in addressing ATTR-CM treatments.
Teladoc Health Vs. Novavax: Stock Picks and Avoidance by Mark Eisenberg 09.04.2024 Teladoc Health's revenue grew by 8% to $2.6 billion in 2023, with a gross margin of 70.8%. On the other ...
3 Ultra-High-Yield Dividend Stocks: Top Buys in April by Mark Eisenberg 08.04.2024 Income seekers can find high-yielding dividend stocks, despite challenges faced by IIP. The COVID-19 pandemic disrupted plans, but coal companies ...
Pfizer and Moderna Stocks: Down 30% and 27% – Buy and Hold by Terry Bingman 06.04.2024 Pfizer and Moderna have struggled in the stock market, but Pfizer has a substantial pipeline of programs. Moderna's success is ...
Pfizer’s Debt Concerns Cast Doubt on Viking Therapeutics Acquisition by Mark Eisenberg 01.04.2024 Pfizer's interest in the weight loss market is uncertain due to its significant debt of over $70 billion and recent ...
Amazon Joins Dow Jones, Walgreens Booted – Bloomberg by Mark Eisenberg 21.02.2024 Amazon.com is set to join the Dow Jones Industrial Average, replacing Walgreens Boots Alliance, while Uber Technologies will replace JetBlue ...
Sosei Heptares: Strategic Wins Propel Growth by Mark Eisenberg 13.02.2024 Sosei Group Corporation announces operational activities and consolidated results, including significant investment, marketing approval, and partnerships. Despite revenue decrease, the ...
Johnson & Johnson vs. Pfizer: Pharmaceutical Industry SWOT by Mark Eisenberg 21.08.2023 The competition between Johnson & Johnson and Pfizer in the pharmaceutical industry is heating up. Here's a SWOT analysis of ...